{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:56:38Z","timestamp":1778237798720,"version":"3.51.4"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Pediatric neurological autoimmune diseases (PNADs) are a result of immune system abnormalities that target the central and peripheral nervous systems, leading to various neurological dysfunctions in children. The limitations of current immunotherapies underscore the necessity for more efficacious treatment interventions. The objective of this review is to examine the fundamental principles, recent advancements, and clinical applications of chimeric antigen receptor (CAR) T cell therapy in the treatment of pediatric neurological autoimmune diseases (PNADs). By specifically targeting and reducing pathogenic B cells, CAR-T therapy has the potential to reset the immune system. Growing evidence from preclinical animal studies, case reports, and early clinical trials suggests that CAR-T cell therapy has therapeutic potential in managing autoimmune diseases such as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and systemic lupus erythematosus (SLE). However, several challenges remain, including the high cost of treatment, safety concerns such as cytokine release syndrome and neurotoxicity, and a lack of long-term safety data in pediatric populations. Future research should prioritize optimizing the management and evaluation model for the entire process, as well as refining CAR design and development, to enhance the safe and effective clinical application of CAR T-cell therapy in patients with PNADs.<\/jats:p>","DOI":"10.3389\/fped.2026.1740566","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:56:13Z","timestamp":1774421773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives"],"prefix":"10.3389","volume":"14","author":[{"given":"Weihao","family":"Ling","sequence":"first","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Children\u2019s Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/B978-0-323-99209-1.00001-6","article-title":"Pediatric inflammatory leukoencephalopathies","volume":"204","author":"Abdel-Mannan","year":"2024","journal-title":"Handb Clin Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0296870","DOI":"10.1371\/journal.pone.0296870","article-title":"Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: exploring psychosis, related risk factors, and hospital outcomes in a nationwide inpatient sample: a cross-sectional study","volume":"19","author":"Jaka","year":"2024","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101118","DOI":"10.1016\/j.spen.2024.101118","article-title":"Pediatric neuroinflammatory diseases in the intensive care unit","volume":"49","author":"Fisher","year":"2024","journal-title":"Semin Pediatr Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.spen.2010.10.007","article-title":"Pharmacologic agents for pediatric neuroimmune disorders","volume":"17","author":"Golumbek","year":"2010","journal-title":"Semin Pediatr Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e213537","DOI":"10.1212\/WNL.0000000000213537","article-title":"Diagnosis and management of children with atypical neuroinflammation","volume":"104","author":"Saucier","year":"2025","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.24272\/j.issn.2095-8137.2021.363","article-title":"Engineered T cells and their therapeutic applications in autoimmune diseases","volume":"43","author":"Bao","year":"2022","journal-title":"Zool Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12969-024-00990-4","article-title":"CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?","volume":"22","author":"Stojkic","year":"2024","journal-title":"Pediatric Rheumatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"661875","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biomedicines9010059","article-title":"Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections","volume":"9","author":"Zmievskaya","year":"2021","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e682","DOI":"10.1212\/NXI.0000000000000682","article-title":"Pediatric autoimmune encephalitis: recognition and diagnosis","volume":"7","author":"de Bruijn","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pediatrneurol.2022.05.004","article-title":"Autoimmune encephalitis in children","volume":"132","author":"Hardy","year":"2022","journal-title":"Pediatr Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1038\/s41594-024-01386-4","article-title":"Structural and functional mechanisms of anti-NMDAR autoimmune encephalitis","volume":"31","author":"Michalski","year":"2024","journal-title":"Nat Struct Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1004559","DOI":"10.1371\/journal.pcbi.1004559","article-title":"Gene expression switching of receptor subunits in human brain development","volume":"11","author":"Bar-Shira","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1093\/cercor\/bhaa052","article-title":"Age-Dependent changes in synaptic NMDA receptor composition in adult human cortical neurons","volume":"30","author":"Pegasiou","year":"2020","journal-title":"Cereb Cortex"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e200080","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/cells12111534","article-title":"CAR-based therapy for autoimmune diseases: a novel powerful option","volume":"12","author":"Muzes","year":"2023","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1126421","DOI":"10.3389\/fimmu.2023.1126421","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1544532","DOI":"10.3389\/fimmu.2025.1544532","article-title":"Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"934343","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"B30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1212\/con.0000000000001464","article-title":"Pediatric autoimmune neurologic disorders","volume":"30","author":"Hacohen","year":"2024","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/03009742.2017.1336570","article-title":"Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial","volume":"47","author":"Emamikia","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1492552","DOI":"10.3389\/fimmu.2024.1492552","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B46","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41584-025-01272-3","article-title":"CAR T cell therapy for children with rheumatic disease: the time is now","volume":"21","author":"Wobma","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","article-title":"Targeting pathogenic CD8(+) tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e200292","DOI":"10.1212\/nxi.0000000000200292","article-title":"CD19-Directed CAR T-cells in a patient with refractory MOGAD","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2022.40.16_suppl.7008","article-title":"Autologous CD19-directed CAR T cells produced by novel PrimeCAR manufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed\/refractory B-lineage acute leukemia (r\/r B-ALL)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","article-title":"Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases","volume":"63","author":"Lyu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jtct.2025.06.026","article-title":"Assessing cognitive function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT","volume":"31","author":"Kennedy","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J Neurol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3390\/biomedicines12071622","article-title":"The kinetics of inflammation-related proteins and cytokines in children undergoing CAR-T cell therapy\u2014are they biomarkers of therapy-related toxicities?","volume":"12","author":"Marschollek","year":"2024","journal-title":"Biomedicines"},{"key":"B60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-025-03564-1","article-title":"CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?","volume":"27","author":"Jouret","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.2024023933","article-title":"Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents","volume":"144","author":"Diorio","year":"2024","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.2017.76.4696","article-title":"Neurocognitive outcomes and interventions in long-term survivors of childhood cancer","volume":"36","author":"Krull","year":"2018","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100237","DOI":"10.1016\/j.ejcped.2025.100237","article-title":"Cognitive and adaptive functioning outcomes after cancer diagnosis in early childhood: a systematic review","volume":"5","author":"Beamish","year":"2025","journal-title":"EJC Paediatric Oncology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2020","journal-title":"Infection"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Cancer Network"},{"key":"B70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/17474086.2022.2069096","article-title":"Systematic review of costs and cost-effectiveness of treatment for relapsed\/refractory acute leukemia in children and young adults","volume":"15","author":"Soliman","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e31802","DOI":"10.1002\/pbc.31802","article-title":"How I approach ethical considerations for pediatric phase I CAR T-cell trials","volume":"72","author":"Peters","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"100373","DOI":"10.1016\/j.esmoop.2021.100373","article-title":"WHO-ESMO collaboration in cancer control: policies into action to save lives","volume":"7","author":"Mikkelsen","year":"2022","journal-title":"ESMO Open"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1533254","DOI":"10.3389\/fimmu.2025.1533254","article-title":"Advance in chimeric antigen receptor T therapy in autoimmune diseases","volume":"16","author":"Ji","year":"2025","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10067-025-07550-5","article-title":"CAR T cells in pediatric systemic lupus erythematosus","volume":"45","author":"Simopoulou","year":"2026","journal-title":"Clin Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"103687","DOI":"10.1016\/j.autrev.2024.103687","article-title":"Harnessing the potential of CAR-T cell in lupus treatment: from theory to practice","volume":"23","author":"Alsuliman","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","article-title":"Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future","volume":"9","author":"Mougiakakos","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cells14010041","article-title":"CAR-T Therapy beyond B-cell hematological malignancies","volume":"14","author":"Canichella","year":"2025","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","first-page":"9917","DOI":"10.1038\/s41467-024-53996-7","article-title":"Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"B80","doi-asserted-by":"publisher","first-page":"850998","DOI":"10.3389\/fimmu.2022.850998","article-title":"Role of the CXCL13\/CXCR5 axis in autoimmune diseases","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejpn.2023.10.001","article-title":"Analysis of the relation between cerebrospinal fluid antibody titers and clinical characteristics in pediatric patients with anti-N-methyl-D-aspartate receptor encephalitis","volume":"47","author":"Yang","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/RLU.0000000000005574","article-title":"Regional metabolic abnormalities in autoimmune encephalitis: a meta-analysis of 498 cases with brain FDG PET","volume":"50","author":"Kosek","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1007\/s00259-025-07305-z","article-title":"Comparison of (18)F-DPA714 PET\/MRI and (18)F-FDG PET\/CT in patients with autoimmune encephalitis: a cross-sectional study","volume":"52","author":"Meng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1740566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:56:15Z","timestamp":1774421775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1740566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":85,"alternative-id":["10.3389\/fped.2026.1740566"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1740566","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"1740566"}}